Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia

Launched by JW PHARMACEUTICAL · Apr 30, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a combination of two medications, JW0108 and C2407, to see how well they work together in treating patients with dyslipidemia, a condition where there are unhealthy levels of fats, like cholesterol and triglycerides, in the blood. The goal is to find out if this combination is safe and effective for helping to manage these levels.

To participate in the trial, you need to be at least 19 years old and have been diagnosed with dyslipidemia. However, if your condition is caused by another disease (called secondary dyslipidemia) or if your fat levels don’t meet specific criteria, you won’t be eligible. For those who join, you can expect to be part of a study where neither you nor the researchers will know which treatment you receive, ensuring unbiased results. This trial is currently not recruiting, so there will be no immediate participation opportunities.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age of 19 years old at the time of written informed consent
• • Patients with dyslipidemia
• Exclusion Criteria:
• • Secondary dyslipidemia
• • Patient who does not meet the specified TG, LDL-C level